Immunic (NASDAQ: IMUX) has announced the appointment of biopharmaceutical executive Michael W. Bonney as chair of its board of directors (BoD), effective May 16, 2026. Simona Skerjanec, MPharm, MBA, will transition from interim chairperson to continue serving as a member of the board.
Mr. Bonney brings more than 30 years of leadership experience across biopharmaceutical commercialization. He played a key role in the launch and commercial success of Avonex for multiple sclerosis.
In a statement, Ms. Skerjanec commented, “I would like to welcome Mike as Chair of the board at what is, without question, a defining stage of growth for Immunic. His extensive experience in biotech and achievements throughout his career as a CEO, chair and member of the board, as well as his MS experience in the launch and growth of Avonex during his time at Biogen are all highly relevant as we advance vidofludimus calcium toward potential regulatory approval and commercial readiness.”
